Last reviewed · How we verify
SC Methylnaltrexone
SC Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that blocks the action of opioids in the gastrointestinal tract.
SC Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that blocks the action of opioids in the gastrointestinal tract. Used for Treatment of opioid-induced constipation in adult patients with advanced illness who have not responded to maximum doses of naloxegol or have a medical contraindication to naloxegol.
At a glance
| Generic name | SC Methylnaltrexone |
|---|---|
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | opioid antagonist |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
By blocking the action of opioids in the gastrointestinal tract, SC Methylnaltrexone reduces the constipating effects of opioids without affecting their analgesic effects. This allows patients to maintain their opioid therapy while minimizing gastrointestinal side effects.
Approved indications
- Treatment of opioid-induced constipation in adult patients with advanced illness who have not responded to maximum doses of naloxegol or have a medical contraindication to naloxegol
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. (PHASE4)
- Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan (PHASE1)
- Open-Label Treatment Extension of Protocol MNTX 301 (PHASE3)
- Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose (PHASE1)
- Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function (PHASE1)
- Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction (PHASE2)
- Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function (PHASE1)
- Open-Label Treatment Extension of Protocol MNTX 302 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC Methylnaltrexone CI brief — competitive landscape report
- SC Methylnaltrexone updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI